Nasdaq GlobeNewswire

CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research

SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology.

Sentia Medical Sciences Inc. Announces the Launch of a New Initiative in Stress-related Disorders Targeting Gastrointestinal and Endocrine Diseases

 

SAN DIEGO, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Sentia announced today that it will bring to fruition several decades of academic research by developing a new generation of first in class drug candidates called astressins. Astressins are peptide antagonists that block the action of corticotropin releasing factor (CRF) and urocortins, the main mediators of the body’s response to stress. CRF and urocortins are the factors that initiate and direct the stress response, and are crucial in controlling the autonomic, behavioral, endocrine, visceral, immune and reproductive responses to stress. Thus, astressins have broad applicability to treat multiple stress-related diseases. The new initiative will firstly prioritize gastrointestinal (GI) diseases and endocrine disorders.

Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran

 

VANCOUVER, B.C. and WARMINSTER, Pa., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy. This submission allows the FDA to review completed portions of the NDA on an ongoing basis. Alnylam expects to submit final clinical data by year end.

Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer

 

Newark, NJ, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a clinical stage company and leader in the field of cancer metabolism-based therapeutics, announced today, the initiation of a Phase I clinical trial of CPI-613 in combination with chemotherapeutic agents, gemcitabine and nab-paclitaxel, for patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in collaboration with Atlantic Health System. CPI-613 is a first-in-class drug with a unique mode of action and is Rafael’s lead altered energy metabolism directed (AEMD) drug candidate. The drug is designed to disrupt the altered energy-production pathways in cancer cells by targeting their mitochondrial metabolism.

AquaBounty wins Gold Leaf Award for Best “Emerging Agriculture Company” from BIOTECanada

MAYNARD, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (NASDAQ:AQB), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), has won the Gold Leaf Award – “Emerging Agriculture Company” from BIOTECanada, Canada’s national biotechnology industry association.

BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference

 

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the 29th Annual Piper Jaffray Healthcare Conference in New York on November 28, 2017 at 3:00 p.m. Eastern Time.

MacroGenics Names Dr. Jay Siegel to its Board of Directors

ROCKVILLE, MD, Nov. 15, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the appointment of Jay Siegel, M.D., former Chief Biotechnology Officer and Head of Scientific Strategy and Policy at Johnson & Johnson, to its Board of Directors. 

Adverum Biotechnologies to Present at Upcoming Conferences

MENLO PARK, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that company executives will present at upcoming conferences in November.

Progressive Care Reports Stellar Third Quarter Results

 

MIAMI, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTC PINK:RXMD), through its subsidiaries Smart Medical Alliance, Inc. and PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals, compounded medications, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long term care facilities, administration and practice management, utilization management, quality assurance, EHR Implementation, billing and coding, and health practice risk management, announces financial results for the third quarter and provides updates on the Company's strategies.

Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update

 

Preliminary Data from PTI-428 + Orkambi 28 Day Clinical Study on Track for Q4 2017 
Initial Data from PTI-801 + Orkambi 14 Day Clinical Trial Anticipated in Q4 2017 
Initial Data from PTI-808 SAD and MAD HV 7 day Study Anticipated in Q4 2017 
Initial Data from PTI-808 + PTI-801 + PTI-428 coadministration HV 7 day Study Anticipated in Q4 2017 
Dual Combination CF Clinical Study of PTI-801 + PTI-808 Expected to Initiate in Q4 2017 
Preliminary Data from PTI-428 + Kalydeco 14 Day Clinical Study Anticipated in Q1 2018 
Triple Combination CF Study of PTI-428 + PTI-801 + PTI-808 Planned to Initiate in 1H 2018

Aptose Reports Results for the Third Quarter Ended September 30, 2017

SAN DIEGO and TORONTO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three months ended September 30, 2017 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars. 

NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer

 

AMES, Iowa, Nov. 14, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Eugene P. Kennedy, M.D., FACS, to the role of Chief Medical Officer. He will be responsible for leading all clinical development, medical affairs and related functions. Dr. Kennedy’s previous role at NewLink Genetics was Vice President of Clinical and Medical Affairs.

Former General Mills Executive Joins Canadian Startup as Advisor

PETERBOROUGH, Ontario, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Noblegen Inc. (“Noblegen”) — announces the appointment of distinguished industry veteran, Jim Kirkwood, as an official advisor to the Corporation.

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights

-Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO- 

CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation

PRO 140 Currently in Phase 2 Clinical Trial in Leukemia Patients Receiving Bone Marrow Transplants

CORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer

 Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed 
Stage III and IV Ovarian Cancer

Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)

 

VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced the grant of an accelerated assessment from the European Medicines Agency (EMA) for patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR (hATTR) amyloidosis. Accelerated assessment may provide a reduced review timeline from 210 to 150 days once the marketing authorization application (MAA) is filed and validated, which Alnylam intends to file by year-end 2017.

Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer

 Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed 
Stage III and IV Ovarian Cancer

Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease

 

BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced an oral presentation titled, “Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients With Stage 3 Chronic Kidney Disease and Persistent High Triglycerides.” This oral presentation was held at the American Heart Association (AHA) 2017 Scientific Sessions in Anaheim, California.

MacroGenics to Participate in Two Upcoming Investor Conferences

ROCKVILLE, MD, Nov. 13, 2017 (GLOBE NEWSWIRE) --